Alpurase

Each tablet contains Allopurinol 300 mg.

Anti-gout.
Allopurinol inhibits the action of the enzyme xanthine oxidase, thus reducing the oxidation of hypoxanthine to xanthine and xanthine to uric acid. The urinary purine load normally almost entirely uric acid is thereby divided between hypoxanthine, xanthine and uric acid each with its independent solubility. This results in the reduction of uric acid concentrations in both plasma and urine ideally to such an extent that deposits of uric acid are dissolved or prevented from forming.
Pharmacokinetics: Absorption and Fate: Allopurinol is absorbed from the gastrointestinal tract after oral administration and is reported to have a plasma t_½ of about 1-3 hrs. It is converted primarily in the liver to oxypurinol (alloxanthine) with a reported t_½ of 18-30 hrs in patients with normal renal function. Allopurinol and oxypurinol are not bound to plasma proteins. Excretion is mainly through the kidney but it is slow. Oxypurinol undergoes glomerular filtration as well as tubular reabsorption.

Used to treat primary or secondary hyperuricemia associated with chronic gout, uric acid nephropathy, recurrent uric acid stone formation, enzyme disorders and cancer therapy. May be used when uricosurics are ineffective or contraindicated. Not used to treat gout although it may prevent attacks.

Children: Under six years old: 150 mg daily.
6 to 10 years old: 300 mg daily adjusted if necessary after 48 hours for hyperuricemia secondary to neoplastic disease.
Adult: Average Daily Dose: 100 to 300 mg for mild gout.
300 to 600 mg for moderately severe gout.
600 to 800 mg for 2 to 3 days for the prevention of acute uric acid nephropathy during therapy with antineoplastic agent or as prescribed by the physician.

This product contains F D & C red #5 (Tartrazine) which may cause allergic reactions in certain susceptible persons (including bronchial asthma).

Allopurinol should not be used for the treatment of an acute attack of gout; moreover, allopurinol therapy should not be initiated for any purpose during an acute attack. Treatment should not be stopped if any skin reactions or other sign of hypersensitivity develops. A cautious reintroduction at a lower dose may be attempted when mild skin reactions have cleared; allopurinol should not be reintroduced in those patients who have experienced other forms of hypersensitivity reactions. Allopurinol should be administered with care to patients with renal or hepatic impairment, and doses may need to be reduced. In all patients receiving allopurinol, it is advisable to maintain a urinary output of not less than 2 L/day and for the urine to be neutral or slightly alkaline.
Use in lactation: Allopurinol should be used with caution in nursing mothers as it has been reported to be excreted in the breast milk.

Use in lactation: Allopurinol should be used with caution in nursing mothers as it has been reported to be excreted in the breast milk.

Store at temperatures not exceeding 30°C.

Hyperuricemia & Gout Preparations

M04AA01 - allopurinol ; Belongs to the class of preparations inhibiting uric acid production. Used in the treatment of gout.

Rx